DAVID SWARTZ, Director at RadNet RDNT , reported an insider sell on March 12, according to a new SEC filing. What Happened: SWARTZ's decision to sell 25,000 shares of RadNet was revealed in a Form 4 ...

Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, and Qureight Ltd, a Core Imaging Laboratory with ...